Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.New Jersey-based Provid Pharmaceuticals has entered into a collaborative research agreement with Immune Control for the development of lead compounds for diseases with immunological causes.
Subscribe to our email newsletter
Provid will employ its expertise in structure-based design, peptide mimetics technology, and medicinal chemistry to develop the lead compounds.
“We are pleased to be complementing the biology of Immune Control with Provid’s chemistry. This collaboration exemplifies the value of Provid’s drug discovery services in transforming targets into valuable drug candidates,” commented Dr Gary Olson, president & CEO of Provid.